Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-180-5 | CAS number: 79-14-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- short-term repeated dose toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 983
- Report date:
- 1983
Materials and methods
- Principles of method if other than guideline:
- Groups of 10 rats were exposed to 0, 0.23, 0.72, and 2.0 mg/L in air for 6 hrs/day, 5 days/week for 2 weeks. At the end of the exposure period and after a 14-day recovery period, blood and urine samples were collected for clinical analysis and rats were sacrificed for pathological examination.
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Glycollic acid
- EC Number:
- 201-180-5
- EC Name:
- Glycollic acid
- Cas Number:
- 79-14-1
- Molecular formula:
- C2H4O3
- IUPAC Name:
- 2-hydroxyacetic acid
- Details on test material:
- Glycolic acid 70% solution
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD®
- Sex:
- male
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- Exposure was for 6 hours per day, 5 days per week for 2 weeks. Due to deteriorating condition in the high dose group, these rats were only dosed on eight occasions.
- Frequency of treatment:
- five days/week for two weeks followed by a 14 day observation period.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0.20, 0.70 and 2.0 mg/L
Basis:
nominal conc.
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent no treatment
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 0.23 mg/L air (nominal)
- Sex:
- male
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Mortality: Exposure of the 2.0 mg/L treatment was stopped after the 8th exposure. Seven of the rats at this treatment were sacrificed in extremis: one after the 8th exposure, four the following day, and one each on the 11th and 12th days after the eighth exposure. A single rat died in the 0.72 mg/L treatment 13 days after the 10th exposure.
Clinical signs: No clinical signs or weight gain differences were seen between the control and 0.23 mg/L animals. Rats in the 0.72 and 2.0 mg/L treatments experienced significant and severe weight loss throughout the exposure and recovery periods. Symptoms of toxicity included laboured breathing, lung noise, ruffled and discoloured fur, red and clear nasal and ocular discharges.
Clinical chemistry: Measurements made at the end of the exposure period showed no compound-related changes in rats exposed to 0.23 mg/L. Changes were noted in the 0.72 and 2.0 mg/L treatments. Rats exposed to 2.0 mg/L had decreased concentrations of serum protein, increased serum activities of glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase, and decreases in urine volume and pH. These changes were interpreted as evidence of compound related effects on the integrity and function of hepatic tissue. However the effects were all reversible following the 14 day recovery period.
Gross necropsy: Gross pathological examination following the exposure period revealed no compound-related changes in rats exposed to 0.23 and 0.72 mg/L. Rats exposed to 2.0 mg/L showed distended G. I. tract, small spleen and small thymus. Similar effects were seen in rats at all test levels 14 days after exposure. Microscopic examination showed mild, diffuse hepatocellular degeneration in one rat in the 0.23 mg/L treatment, 9 rats in the 0.72 and 7 rats at 2.0 mg/L. A comparison of organ and body weights between control and rats at 0.243 mg/L showed no changes. Effects were seen in rats exposed to 0.72 and 2.0 mg/L. Fourteen days later, rats exposed to 0.72 mg/L had significantly lower lung, kidney, liver and thymus weights than control rats. Rats exposed to 2.0 mg/L had significantly lower kidney weights. On an organ/body weight basis, rats exposed to 0.72 mg/L had elevated testes weights.
Applicant's summary and conclusion
- Conclusions:
- Based on parameters evaluated in this study, the 0.72 and 2.0 mg/l treatments are definite and dose-dependent effect levels with the primary effects on survival and on hepatic integrity. The only effect seen at 0.23 mg/L was very mild diffuse hepatocellular degeneration in one of ten rats, 14 days post exposure. Based on the steepness of the dose-response curve (disappearance of mortality, weight loss and clinical signs with concentration) this level is practically a no-effect level. NOAEL = 0.23 mg/L for repeated administration by inhalation exposure.
- Executive summary:
Groups of 10 rats were exposed to 0, 0.23, 0.72, and 2.0 mg/L in air for 6 hrs/day, 5 days/week for 2 weeks. At the end of the exposure period and after a 14-day recovery period, blook and urine samples were collected for clinical analysis and rats were sacrificed for patological examination. Based on parameters evaluated in this study, the 0.72 and 2.0 mg/l treatments are definite and dose-dependent effect levels with the primary effects on survival and on hepatic integrity. The only effect seen at 0.23 mg/L was very mild diffuse hepatocellular degeneration in one of ten rats, 14 days post exposure. Based on the steepness of the dose-response curve (disappearance of mortality, weight loss and clinical signs with concentration) this level is practically a no-effect level. NOAEL = 0.23 mg/L for repeated administration by inhalation exposure.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.